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Mutation epidemiology in each ethnic group is important for cystic fibrosis diagnosis and genetic counselling. To date, little has been reported
on the prevalence of cystic fibrosis in the Ecuadorian population where the mutation distribution appears to differ from that of Europe. We present
a series of four Ecuadorian patients homozygous for the H609R mutation in the CFTR gene. This is the first report of detection of this mutation in
the Ecuadorian population. Taking advantage of the homozygous status of the patients, an evaluation of the most important clinical parameters is
presented. From the diagnostic point of view, the information provided by our study is of relevance in designing an appropriate strategy for genetic
testing of patients in Ecuador and in European countries where immigration from Ecuador is common.
© 2009 European Cystic Fibrosis Society. Published by Elsevier B.V. All rights reserved.Keywords: CFTR gene; Cystic fibrosis; Ecuador; H609R; Mutation1. Introduction
Cystic fibrosis (CF) is one of the most common and serious
autosomal recessive disorders among Caucasians with an
estimated incidence of 1:2500. The clinical spectrum of the
disease is heterogeneous but most patients with CF typically
present with chronic obstructive lung disease, exocrine
pancreatic insufficiency and male infertility [1,2]. CF is caused
by mutations in gene coding for the cystic fibrosis transmem-
brane conductance regulator (CFTR). To date more than 1500
CFTR mutations have been reported to the Cystic Fibrosis
Genetic Analysis Consortium [3], although fewer than 20 have
been reported worldwide at a frequency of greater than 0.1%.
However, some mutations can reach a higher frequency in
certain populations, due to a founder effect in religious, ethnic
or geographical isolates [4,5].
The belief that CF was typically a disease of northern
Europeans and Anglo-Saxon descended populations has⁎ Corresponding author. Tel.: +34 968889860; fax: +34 968889861.
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There are two other reports of mutations on the CFTR gene in
CF patients from Ecuador; in the first, the estimated Ecuadorian
CF incidence was 1:11,252 and mutations were, in order of
frequency, F508del (37.1%), G85E (8.9%), G542X (2.4%),
N1303K (2.4%), G551D (1.6%) and R334W (0.8%), with a
detection rate of 53.22% of the total CF chromosomes studied
[7]. In the second report, a compilation of data from CFTR gene
analysis in Latin American CF patients, four mutations were
found: F508del (31.37%), G542X (1.96%), G85E (1.96%) and
N1303K (1.96%), with 63.7% of Ecuadorian CF mutations
remaining unidentified [6].
2. Materials and methods
A total of 6 Ecuadorian CF patients were included in the
study. Genomic DNA was extracted from peripheral blood
lymphocytes by standard methods. The analysis of CFTR
common mutations was carried out by multiplex mutation
analysis with the PCR OLA CF Genotyping Assay (Abbott,
Wiesbaden, Germany), according to the manufacturer'sd by Elsevier B.V. All rights reserved.
Table 1
Clinical phenotypes of patients homozygous for H609R mutation.
Patient 1 a Patient 2 a Patient 3 Patient 4
Sex Female Female Female Male
Age at diagnosis 3 years 5 years Neonatal 28 years
Age at time of study 15 years 17 years 2 months 29 years
Pancreatic insufficiency Yes Yes ND No
FEV1 (% predicted) 75% 50% ND 36%
Pseudomonas aeruginosa
colonization
Yes Yes ND Yes
Sweat Cl (mEq/L) N60 N60 67 83
Other – – – CBAVD
FEV1, forced expiratory volume in 1 s; CBAVD, congenital bilateral absence of
vas deferens; ND, not determined.
a Siblings.
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mutations were analysed by sequencing of the entire coding
sequence and flanking intronic sequences [8] using the Big Dye
Terminator Cycle Sequencing Kit (PE Applied Biosystems,
Foster City, CA) on an ABI 3130 Genetic Analyzer.
The study was approved by the local ethics committee and
written consent was obtained from all subjects or their parents.
3. Case reports
The four CF patients homozygous for the mutation H609R in
the CFTR gene were identified among the six Ecuadorian
patients diagnosed at the CF Unit at University Hospital
Virgen Arrixaca in Murcia (Spain) and their clinical phenotypes
are shown in Table 1. Genotypes G85E/G85E and G85E/S549R
were found in the other two patients.
The H609R mutation was identified by sequencing after
genotype testing for the most common CFTR mutations
revealed a negative result. In the three families, not known to
be related, the parents were not consanguineous. The homo-
zygous status in all patients was confirmed by studying the
parents. In all cases, the sweat chloride test was abnormal
(N60 mEq/L), and the mutation H609R was associated with a
severe CF phenotype based on clinical features.
4. Discussion
The mutation H609R is caused by the transition of an A to G
at nucleotide 1958 in exon 13, and results in the substitution of a
histidine to an arginine at position 609 of the protein, a mutation
first described by Bienvenu et al. [3] in a CF patient from
Columbia but unfortunately, no clinical data were available. On
literature review, this mutation has not been found in any other
population. Thus, this is the first report of detection of the
H609R mutation in the Ecuadorian population. It is interesting
to note that these patients would not have been genetically
identified using the current recommended panel for CFTR
genetic analysis, particularly the panel based on the American
College of Medical Genetics guidelines [9]. Therefore, thereport also illustrates the limitations inherent in the use of
mutation panels and the need for complete CFTR analysis or
more extensive mutation panels.
The precise phenotypic consequences of the various CFTR
mutations are important to establish, both for prognosis and
genetic counselling. The four patients in our study, all
homozygous for mutation H609R, provide some help in
understanding the effect of this mutation on CFTR gene
function, showing it to be a severe mutation, associated with
typical CF.
Although further studies of greater numbers of Ecuadorian
CF patients should be carried out to determine the frequency of
the H609R mutation in this ethnic group, our study is important
in relation to testing for CF in Ecuador and in European
countries where immigration from Ecuador is common. A
knowledge of the molecular genetic epidemiology of CF in each
ethnic group is important in order to apply more appropriate and
cost-effective diagnostic molecular genetic studies. Our results
suggest that Ecuadorian patients whose CF mutations test
negative using standard commercial panels should have direct
analysis of mutation H609R since this may be a common
mutation in this ethnic group, possibly accounting for a
significant percentage of unidentified CF alleles.
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